Targeted lipid nanoparticles (tLNPs) are advancing in vivo CAR-T therapies by facilitating the in situ generation of CAR-T effectors, offering...

CAR-T therapies have transformed the treatment of hematologic malignancies, yet complex manufacturing, long production timelines, and high costs continue to...